newsfilter
← Latest News
GlobeNewswire·

MHRA approves Pharming’s Joenja® (leniolisib) as first treatment specifically for children with APDS in the U.K.

Approval extends existing U.K. indication for Joenja to eligible children aged 4 to 11 who weigh at least 27 kgJoenja is expected to become available to patients covered by the expanded indication in February 2027Marks